Tocqueville Asset Management L.P. Sells 166,090 Shares of Pfizer Inc. (NYSE:PFE)

Tocqueville Asset Management L.P. lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,211,335 shares of the biopharmaceutical company's stock after selling 166,090 shares during the quarter. Tocqueville Asset Management L.P.'s holdings in Pfizer were worth $32,137,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Flagship Wealth Advisors LLC bought a new stake in shares of Pfizer during the fourth quarter worth $420,000. Horizon Kinetics Asset Management LLC grew its stake in shares of Pfizer by 7.3% during the fourth quarter. Horizon Kinetics Asset Management LLC now owns 100,703 shares of the biopharmaceutical company's stock worth $2,672,000 after buying an additional 6,888 shares during the last quarter. Curio Wealth LLC bought a new stake in shares of Pfizer during the fourth quarter worth $32,000. Pitti Group Wealth Management LLC bought a new stake in shares of Pfizer during the fourth quarter worth $375,000. Finally, Cibc World Markets Corp grew its stake in shares of Pfizer by 17.3% during the fourth quarter. Cibc World Markets Corp now owns 902,242 shares of the biopharmaceutical company's stock worth $23,936,000 after buying an additional 133,084 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.4 %

PFE traded down $0.12 during midday trading on Wednesday, hitting $26.19. The company had a trading volume of 24,966,825 shares, compared to its average volume of 35,756,685. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $148.44 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. The stock's 50 day moving average price is $26.21 and its 200 day moving average price is $27.09.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the firm posted $0.10 earnings per share. The business's revenue was up 24.7% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on PFE. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.